{"id":"orphenadrine","rwe":[{"pmid":"41679394","year":"2026","title":"Neuroprotective potential of orphenadrine in focal cerebral ischemia: A neurobehavioral and mechanistic study.","finding":"","journal":"Toxicology and applied pharmacology","studyType":"Clinical Study"},{"pmid":"41370840","year":"2025","title":"A Treatment Approach for Severe Pain in Mast Cell Activation Syndrome: A Case Report.","finding":"","journal":"A&A practice","studyType":"Clinical Study"},{"pmid":"41115038","year":"2025","title":"The Physical Compatibility of Orphenadrine Citrate with 0.45% Sodium Chloride, Lactated Ringer's Solution, and Plasma-Lyte A.","finding":"","journal":"International journal of pharmaceutical compounding","studyType":"Clinical Study"},{"pmid":"40670997","year":"2025","title":"Association of medication adherence and glycemic control with pain severity among patients with diabetes mellitus: a cross-sectional study from Palestine.","finding":"","journal":"BMC endocrine disorders","studyType":"Clinical Study"},{"pmid":"40582006","year":"2025","title":"Physicochemical and Microbiological Stability of Commonly Prescribed APIs in SyrSpend® SF PH4: A Comprehensive Compatibility Study.","finding":"","journal":"International journal of pharmaceutical compounding","studyType":"Clinical Study"}],"_fda":{"id":"47f8f308-ca39-d280-e063-6394a90a49e9","set_id":"106be130-b4f8-5ca1-e063-6294a90a1590","openfda":{"unii":["X0A40N8I4S"],"route":["ORAL"],"rxcui":["994521"],"spl_id":["47f8f308-ca39-d280-e063-6394a90a49e9"],"brand_name":["ORPHENADRINE CITRATE"],"spl_set_id":["106be130-b4f8-5ca1-e063-6294a90a1590"],"package_ndc":["82868-040-14"],"product_ndc":["82868-040"],"generic_name":["ORPHENADRINE CITRATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["ORPHENADRINE CITRATE"],"manufacturer_name":["Northwind Health Company, LLC"],"application_number":["ANDA040284"],"original_packager_product_ndc":["43386-480"]},"version":"2","warnings":["WARNINGS Some patients may experience transient episodes of light-headedness, dizziness or syncope. Orphenadrine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; ambulatory patients should therefore be cautioned accordingly."],"pregnancy":["Pregnancy Pregnancy Category C Animal reproduction studies have not been conducted with orphenadrine. It is also not known whether orphenadrine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Orphenadrine should be given to a pregnant woman only if clearly needed."],"overdosage":["OVERDOSAGE Orphenadrine is toxic when overdosed and typically induces anticholinergic effects. In a review of orphenadrine toxicity, the minimum lethal dose was found to be 2 to 3 grams for adults; however, the range of toxicity is variable and unpredictable. Treatment for orphenadrine overdose is evacuation of stomach contents (when necessary), charcoal at repeated doses, intensive monitoring, and appropriate supportive treatment of any emergent anticholinergic effects."],"description":["DESCRIPTION Orphenadrine citrate is the citrate salt of orphenadrine. It occurs as a white, crystalline powder having a bitter taste. It is practically odorless; sparingly soluble in water, slightly soluble in alcohol. The chemical name of orphenadrine citrate is (±) -N,N -Dimethyl-2-[( o -methyl-α-phenylbenzyl)oxy]ethylamine citrate (1:1) having molecular formula C 18 H 23 NO•C 6 H 8 O 7 and molecular weight of 461.51. It has the following structural formula: Each tablet for oral administration contains 100 mg orphenadrine citrate. Each Orphenadrine citrate extended- release tablet contains the following inactive ingredients: hydroxypropyl methylcellulose, lactose monohydrate and magnesium stearate. Image"],"precautions":["PRECAUTIONS Confusion, anxiety and tremors have been reported in few patients receiving propoxyphene and orphenadrine concomitantly. As these symptoms may be simply due to an additive effect, reduction of dosage and/or discontinuation of one or both agents is recommended in such cases. Orphenadrine citrate should be used with caution in patients with tachycardia, cardiac decompensation, coronary insufficiency, cardiac arrhythmias. Safety of continuous long-term therapy with orphenadrine has not been established. Therefore, if orphenadrine is prescribed for prolonged use, periodic monitoring of blood, urine and liver function values is recommended. Pregnancy Pregnancy Category C Animal reproduction studies have not been conducted with orphenadrine. It is also not known whether orphenadrine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Orphenadrine should be given to a pregnant woman only if clearly needed. Pediatric Use Safety and effectiveness in pediatric patients have not been established."],"how_supplied":["HOW SUPPLIED Orphenadrine citrate extended-release tablets 100 mg are round, white to off-white tablets, debossed NL4 on one side and plain on the other side and are supplied as: NDC 82868-040-14 in bottles of 14 tablets Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container. LUPIN and the are registered trademarks of Lupin Pharmaceuticals, Inc. Manufactured by Novel Laboratories, Inc. Somerset, NJ 08873 Manufactured For Lupin Pharmaceuticals, Inc. Naples FL, 34108 SAP Code: 276510 Rev: 10/2024 lupin symbol"],"pediatric_use":["Pediatric Use Safety and effectiveness in pediatric patients have not been established."],"effective_time":"20260101","adverse_reactions":["ADVERSE REACTIONS Adverse reactions of orphenadrine are mainly due to the mild anticholinergic action of orphenadrine, and are usually associated with higher dosage. Dryness of the mouth is usually the first adverse effect to appear. When the daily dose is increased, possible adverse effects include: tachycardia, palpitation, urinary hesitancy or retention, blurred vision, dilatation of pupils, increased ocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, hypersensitivity reactions, pruritus, hallucinations, agitation, tremor, gastric irritation, and rarely urticaria and other dermatoses. Infrequently, an elderly patient may experience some degree of mental confusion. These adverse reactions can usually be eliminated by reduction in dosage. Very rare cases of aplastic anemia associated with the use of orphenadrine tablets have been reported. No causal relationship has been established."],"contraindications":["CONTRAINDICATIONS Orphenadrine citrate extended-release tablets are contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (mega-esophagus) and myasthenia gravis. Orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY The mode of therapeutic action has not been clearly identified, but may be related to its analgesic properties. Orphenadrine citrate does not directly relax tense muscles in man. Orphenadrine citrate also possesses anti-cholinergic actions."],"indications_and_usage":["INDICATIONS AND USAGE Orphenadrine citrate extended-release tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Adults Two tablets per day; one in the morning and one in the evening."],"drug_abuse_and_dependence":["DRUG ABUSE AND DEPENDENCE Orphenadrine has been chronically abused for its euphoric effects. The mood elevating effects may occur at therapeutic doses of orphenadrine."],"spl_product_data_elements":["ORPHENADRINE CITRATE ORPHENADRINE CITRATE HYPROMELLOSES LACTOSE MONOHYDRATE MAGNESIUM STEARATE ORPHENADRINE CITRATE ORPHENADRINE NL4"],"package_label_principal_display_panel":["Principal Display Panel NDC: 82868-040-14 Label"]},"tags":[{"label":"Muscle Relaxant","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Histamine H1 receptor","category":"target"},{"label":"HRH1","category":"gene"},{"label":"CHRM4","category":"gene"},{"label":"CHRM5","category":"gene"},{"label":"M03BC01","category":"atc"},{"label":"Intramuscular","category":"route"},{"label":"Oral","category":"route"},{"label":"Injection","category":"form"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Parkinsonism","category":"indication"},{"label":"Spasticity","category":"indication"},{"label":"Approved 1950s","category":"decade"},{"label":"Anti-Dyskinesia Agents","category":"pharmacology"},{"label":"Antiparkinson Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Cholinergic Agents","category":"pharmacology"},{"label":"Cholinergic Antagonists","category":"pharmacology"},{"label":"Cytochrome P-450 CYP2B6 Inhibitors","category":"pharmacology"},{"label":"Cytochrome P-450 Enzyme Inhibitors","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Metabolic Side Effects of Drugs and Substances","category":"pharmacology"},{"label":"Muscarinic Antagonists","category":"pharmacology"},{"label":"Muscle Relaxants, Central","category":"pharmacology"},{"label":"Neuromuscular Agents","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Parasympatholytics","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"69 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"68 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"53 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"50 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"50 reports"},{"date":"","signal":"ANXIETY","source":"FDA FAERS","actionTaken":"49 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"44 reports"},{"date":"","signal":"ARTHRALGIA","source":"FDA FAERS","actionTaken":"43 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"43 reports"},{"date":"","signal":"DRUG HYPERSENSITIVITY","source":"FDA FAERS","actionTaken":"40 reports"}],"drugInteractions":[{"url":"/drug/sodium-oxybate","drug":"sodium oxybate","action":"Avoid combination","effect":"May interact with Sodium Oxybate","source":"DrugCentral","drugSlug":"sodium-oxybate"}],"commonSideEffects":[{"effect":"Pneumonia viral","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Soft tissue disorder","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Herpes zoster","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Oral pain","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Fibromyalgia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Liver function test abnormal","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Blood cholesterol increased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Leukopenia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Arthritis","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Peripheral swelling","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Synovitis","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Tenderness","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Sternal fracture","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Soft tissue injury","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Post-traumatic neck syndrome","drugRate":"","severity":"common","_validated":false,"_confidence":0.3}],"contraindications":["Achalasia of esophagus","Acute erosive gastritis","Acute nephropathy","Agoraphobia","Alcoholism","Anemia","Anemia due to enzyme deficiency","Benign prostatic hyperplasia","Bladder outflow obstruction","Breastfeeding (mother)","Chronic myocardial ischemia","Conduction disorder of the heart","Decompensated cardiac failure","Disease of liver","Factor II deficiency","Gastrointestinal hemorrhage","Gastrointestinal ulcer","Glaucoma","Gout","Hemophilia","Hepatic failure","Hypertensive disorder","Impaired renal function disorder","Insomnia","Kidney disease"],"specialPopulations":{"Pregnancy":"Safe use of orphenadrine has not been established with respect to adverse effects upon fetal development. Therefore, orphenadrine should be used in women of childbearing potential and particularly during early pregnancy only when in the judgment of the physician the potential benefits outweigh the possible hazards.","Paediatric use":"Safety and effectiveness in children have not been established; therefore, this drug is not recommended for use in the pediatric age group."}},"trials":[],"aliases":[],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-12-18","unitCost":"$5.7414/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$2,067","description":"ORPHENADRINE 60 MG/2 ML VIAL","retrievedDate":"2026-04-07"}],"_fixedAt":"2026-03-30T18:31:27.792534","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ORPHENADRINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:40:55.771892+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Orphenadrine","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:41:03.266084+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:41:01.178908+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:40:54.895859+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ORPHENADRINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:41:02.207987+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:40:52.052494+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:41:12.776626+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:40:52.052512+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:41:04.335676+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL900/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:41:02.914156+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA040284","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:40:52.052515+00:00"}},"allNames":"norflex","offLabel":[],"synonyms":["disipal","orphenadrine","orphenadine","orphenadrin","orphenadrine citrate","orphenadrine hydrochloride","orphenadrine (chloride)","orphenadrine HCl"],"timeline":[{"date":"1957-05-10","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"approvals":[{"date":"1957-05-10","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Norflex","ecosystem":[{"indication":"Parkinsonism","otherDrugs":[{"name":"amantadine","slug":"amantadine","company":"Endo Pharms"},{"name":"benzatropine","slug":"benzatropine","company":""},{"name":"biperiden","slug":"biperiden","company":"Abbvie"},{"name":"carbidopa","slug":"carbidopa","company":"Merck Sharp Dohme"}],"globalPrevalence":null},{"indication":"Spasticity","otherDrugs":[{"name":"caffeine","slug":"caffeine","company":"Novartis"},{"name":"carisoprodol","slug":"carisoprodol","company":"Meda Pharms"},{"name":"chlorphenesin carbamate","slug":"chlorphenesin-carbamate","company":"Pharmacia And Upjohn"},{"name":"chlorzoxazone","slug":"chlorzoxazone","company":"Janssen R And D"}],"globalPrevalence":null}],"mechanism":{"target":"Histamine H1 receptor","novelty":"First-in-class","targets":[{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor"},{"gene":"CHRM4","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M4","protein":"Muscarinic acetylcholine receptor M4"},{"gene":"CHRM5","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M5","protein":"Muscarinic acetylcholine receptor M5"},{"gene":"CHRM3","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M3","protein":"Muscarinic acetylcholine receptor M3"},{"gene":"CHRM1","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M1","protein":"Muscarinic acetylcholine receptor M1"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"CHRM2","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M2","protein":"Muscarinic acetylcholine receptor M2"},{"gene":"SLC6A4","source":"DrugCentral","target":"Sodium-dependent serotonin transporter","protein":"Sodium-dependent serotonin transporter"},{"gene":"HTR2C","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2C","protein":"5-hydroxytryptamine receptor 2C"},{"gene":"CYP2D6","source":"DrugCentral","target":"Cytochrome P450 2D6","protein":"Cytochrome P450 2D6"}],"modality":"Small Molecule","drugClass":"Muscle Relaxant","explanation":"","oneSentence":"","technicalDetail":"Orphenadrine acts as a competitive antagonist at the histamine H1 receptor, inhibiting the histaminergic neurotransmission and reducing the excitability of the motor neurons, which leads to muscle relaxation."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Orphenadrine","title":"Orphenadrine","extract":"Orphenadrine is an anticholinergic drug of the ethanolamine antihistamine class; it is closely related to diphenhydramine. It is a muscle relaxant that is used to treat muscle pain and to help with motor control in Parkinson's disease, but has largely been superseded by newer drugs. It is considered a dirty drug due to its multiple mechanisms of action in different pathways. It was discovered and developed in the 1940s.","wiki_history":"== History ==\nGeorge Rieveschl was a professor of chemistry at the University of Cincinnati and led a research program working on antihistamines. In 1943, one of his students, Fred Huber, synthesized diphenhydramine.  Rieveschl worked with Parke-Davis to test the compound, and the company licensed the patent from him.  In 1947 Parke-Davis hired him as their Director of Research.  While he was there, he led the development of orphenadrine, an analog of diphenhydramine.\n\nPrior to the development of amantadine in the late 1960s and then other drugs, anticholinergics like orphenadrine were the mainstay of Parkinson's treatment."},"commercial":{"launchDate":"1957","_launchSource":"DrugCentral (FDA 1957-05-10, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1999","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ORPHENADRINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ORPHENADRINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Orphenadrine","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:09:15.742707","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:41:12.908038+00:00","fieldsConflicting":16,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"acetylcholine","drugSlug":"acetylcholine","fdaApproval":"1973-10-09","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"aclidinium bromide","drugSlug":"aclidinium-bromide","fdaApproval":"2012-07-23","patentExpiry":"Mar 13, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amiodarone","drugSlug":"amiodarone","fdaApproval":"1985-12-24","patentExpiry":"Mar 13, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amitriptyline","drugSlug":"amitriptyline","fdaApproval":"1961-04-07","genericCount":33,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amoxapine","drugSlug":"amoxapine","fdaApproval":"1980-09-22","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"aripiprazole","drugSlug":"aripiprazole","fdaApproval":"2002-11-15","patentExpiry":"Sep 24, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"asenapine","drugSlug":"asenapine","fdaApproval":"2009-08-13","patentExpiry":"Sep 22, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"astemizole","drugSlug":"astemizole","fdaApproval":"1988-12-31","relationship":"same-target"},{"drugName":"atropine","drugSlug":"atropine","fdaApproval":"1960-09-15","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"azelastine","drugSlug":"azelastine","fdaApproval":"1996-11-01","patentExpiry":"Jun 4, 2028","patentStatus":"Patent protected","relationship":"same-target"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"orphenadrine","indications":{"approved":[{"id":"orphenadrine-acute-painful-musculoskeletal-","name":"Acute painful musculoskeletal conditions","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with acute painful musculoskeletal conditions","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with acute painful musculoskeletal conditions","diagnosticRequired":null,"brandNameForIndication":"Norflex"}],"offLabel":[],"pipeline":[]},"_fixedFields":["pubmed(515)"],"currentOwner":"Pai Holdings Pharm","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"acetylcholine","brandName":"acetylcholine","genericName":"acetylcholine","approvalYear":"1973","relationship":"same-target"},{"drugId":"aclidinium-bromide","brandName":"aclidinium bromide","genericName":"aclidinium bromide","approvalYear":"2012","relationship":"same-target"},{"drugId":"amiodarone","brandName":"amiodarone","genericName":"amiodarone","approvalYear":"1985","relationship":"same-target"},{"drugId":"amitriptyline","brandName":"amitriptyline","genericName":"amitriptyline","approvalYear":"1961","relationship":"same-target"},{"drugId":"amoxapine","brandName":"amoxapine","genericName":"amoxapine","approvalYear":"1980","relationship":"same-target"},{"drugId":"aripiprazole","brandName":"aripiprazole","genericName":"aripiprazole","approvalYear":"2002","relationship":"same-target"},{"drugId":"asenapine","brandName":"asenapine","genericName":"asenapine","approvalYear":"2009","relationship":"same-target"},{"drugId":"astemizole","brandName":"astemizole","genericName":"astemizole","approvalYear":"1988","relationship":"same-target"},{"drugId":"atropine","brandName":"atropine","genericName":"atropine","approvalYear":"1960","relationship":"same-target"},{"drugId":"azelastine","brandName":"azelastine","genericName":"azelastine","approvalYear":"1996","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT07109882","phase":"PHASE4","title":"Effectiveness of Chlorzoxazone Versus Orphenadrine Citrate in Alleviating Bruxism Pain","status":"RECRUITING","sponsor":"University of Baghdad","startDate":"2025-07-22","conditions":["Orofacial Pain","Bruxism"],"enrollment":60,"completionDate":"2025-08-30"},{"nctId":"NCT06628466","phase":"","title":"Clinical Response of Nuberol Forte in Chronic Neck Pain in Routine Rehabilitation Centers","status":"COMPLETED","sponsor":"The Searle Company Limited Pakistan","startDate":"2022-11-25","conditions":["Chronic Neck Pain"],"enrollment":150,"completionDate":"2024-01-15"},{"nctId":"NCT05322603","phase":"NA","title":"Efficiency and Safety a Fixed Combination of Orphenadrine and Diclofenac for Postoperative Analgesia","status":"COMPLETED","sponsor":"Petrovsky National Research Centre of Surgery","startDate":"2022-03-18","conditions":["Analgesia"],"enrollment":60,"completionDate":"2022-08-20"},{"nctId":"NCT03493490","phase":"PHASE4","title":"Neodolpasse® Infusion Solution Versus Diclofenac 75 mg Infusion in the Treatment of Postoperative Pain After Elective Knee Surgery","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2018-03-01","conditions":["Pain, Postoperative","Analgesic Adverse Reaction","Cruciate Ligament Rupture"],"enrollment":72,"completionDate":"2019-05-31"},{"nctId":"NCT05413902","phase":"PHASE4","title":"Multi-Modal Anesthesia Protocol in Pain Management of Patients Undergoing Posterior Lumbar Spinal Fusion Surgery","status":"COMPLETED","sponsor":"University of Puerto Rico","startDate":"2021-04-05","conditions":["Pain Management","Posterior Spinal Fusion"],"enrollment":100,"completionDate":"2022-03-23"},{"nctId":"NCT04509336","phase":"NA","title":"Orphenadrine Versus Baclofen in Treatment of Muscle Cramps in Cirrhotic Patients","status":"TERMINATED","sponsor":"Mansoura University","startDate":"2020-08-20","conditions":["Cirrhosis"],"enrollment":5,"completionDate":"2021-09-20"},{"nctId":"NCT04765787","phase":"","title":"Safety & Efficacy of Nuberol Forte® in Pain Management","status":"COMPLETED","sponsor":"The Searle Company Limited Pakistan","startDate":"2020-11-25","conditions":["Musculoskeletal Disorder","Pain Management"],"enrollment":399,"completionDate":"2021-08-01"},{"nctId":"NCT04835116","phase":"PHASE4","title":"Comparison of Post-Operative Analgesia After Percutaneous Nephrolithotomy.","status":"COMPLETED","sponsor":"Armed Forces Institute of Urology, Rawalpindi","startDate":"2019-04-11","conditions":["Pain","Postoperative Pain"],"enrollment":68,"completionDate":"2019-10-11"},{"nctId":"NCT02985671","phase":"PHASE3","title":"To Evaluate the Superiority of Fixed Combination (Orfenadrine 35mg, Acetaminophen 325mg, Caffeine 65mg and Diclofenac Sodium 50mg) Compared to Voltaren® (Diclofenac Sodium 50mg) in the Treatment of Acute Postural Low Back Pain.","status":"UNKNOWN","sponsor":"Ache Laboratorios Farmaceuticos S.A.","startDate":"2021-01","conditions":["Postural Low Back Pain","Mechanical Low Back Pain"],"enrollment":110,"completionDate":"2021-10"},{"nctId":"NCT01263652","phase":"NA","title":"Patient Preferences, Analgesic Delivery Method and Pain Reduction in Spine Patients","status":"WITHDRAWN","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2010-12-31","conditions":["Pain Relief"],"enrollment":0,"completionDate":"2019-06-01"},{"nctId":"NCT02423395","phase":"PHASE3","title":"Study of Orphenadrine' in the Treatment of Muscle Cramps in Patients With Cirrhosis","status":"RECRUITING","sponsor":"Sherief Abd-Elsalam","startDate":"2015-01","conditions":["Liver Cirrhosis","Muscle Cramps"],"enrollment":100,"completionDate":"2028-12"},{"nctId":"NCT02665286","phase":"PHASE4","title":"Orphenadrine and Methocarbamol for LBP","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2016-03","conditions":["Low Back Pain"],"enrollment":240,"completionDate":"2017-05"},{"nctId":"NCT02449369","phase":"PHASE4","title":"Intra-Venous Acetaminophen and Muscle Relaxants After Total Knee","status":"COMPLETED","sponsor":"AdventHealth","startDate":"2015-04","conditions":["Unilateral Knee Arthroplasty"],"enrollment":180,"completionDate":"2016-09"},{"nctId":"NCT02958566","phase":"PHASE4","title":"Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery","status":"UNKNOWN","sponsor":"University of Illinois College of Medicine at Peoria","startDate":"2017-01","conditions":["Colon Cancer","Colon Diverticulosis","Colonic Neoplasms","Colonic Diverticulitis","Pain, Postoperative","Ileus","Ileus Paralytic","Ileus; Mechanical","Constipation Drug Induced","Constipation","Rectum Cancer","Rectum Neoplasm"],"enrollment":80,"completionDate":"2018-12"},{"nctId":"NCT02445599","phase":"PHASE4","title":"Diclofenac Premedication, as the Effect of Preemptive Analgesia After Post-thoracotomy Chest and Shoulder Pain","status":"COMPLETED","sponsor":"University of Debrecen","startDate":"2014-04","conditions":["Pain","Inadequate or Impaired Respiratory Function"],"enrollment":3,"completionDate":"2016-04"},{"nctId":"NCT02485145","phase":"EARLY_PHASE1","title":"The Analgesic Activity of a Topical Formulation in Patients With Osteoarthritis of the Hands","status":"UNKNOWN","sponsor":"Transdermal Therapeutics, Inc.","startDate":"2015-07","conditions":["Osteoarthritis of the Hands"],"enrollment":40,"completionDate":"2016-03"},{"nctId":"NCT02456116","phase":"NA","title":"Efficiency Study About the Effect of Acupuncture on Postoperative Pain After Total Knee Arthroplasty","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2012-09","conditions":["Pain, Postoperative"],"enrollment":90,"completionDate":"2015-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Injection, Tablet","formulations":[{"form":"INJECTION","route":"INTRAMUSCULAR","productName":"Orphenadrine Citrate"},{"form":"INJECTION","route":"INTRAMUSCULAR","productName":"Orphenadrine citrate"},{"form":"TABLET","route":"ORAL","productName":"Norgesic"},{"form":"TABLET","route":"ORAL","productName":"ORPHENGESIC FORTE"},{"form":"TABLET","route":"ORAL","productName":"Orphenadrine Citrate"},{"form":"TABLET","route":"ORAL","productName":"Orphenadrine Citrate Aspirin Caffeine"},{"form":"TABLET","route":"ORAL","productName":"Orphenadrine Citrate, Aspirin and Caffeine"},{"form":"TABLET, EXTENDED RELEASE","route":"ORAL","productName":"ORPHENADRINE CITRATE"},{"form":"TABLET, EXTENDED RELEASE","route":"ORAL","productName":"Orphenadrine Citrate"},{"form":"TABLET, EXTENDED RELEASE","route":"ORAL","productName":"Orphenadrine CitrateER"},{"form":"TABLET, MULTILAYER","route":"ORAL","productName":"Norgesic Forte"},{"form":"TABLET, MULTILAYER","route":"ORAL","productName":"Orphenadrine Citrate, Aspirin and Caffeine"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147952","MMSL":"4456","NDDF":"001648","UNII":"AL805O9OG9","VUID":"4019866","CHEBI":"CHEBI:7789","VANDF":"4018819","INN_ID":"658","RXNORM":"155039","UMLSCUI":"C0029309","chemblId":"CHEMBL900","ChEMBL_ID":"CHEMBL900","KEGG_DRUG":"D00774","DRUGBANK_ID":"DB01173","PUBCHEM_CID":"4601","SNOMEDCT_US":"35035001","IUPHAR_LIGAND_ID":"7251","SECONDARY_CAS_RN":"4682-36-4","MESH_DESCRIPTOR_UI":"D009966"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Pai Holdings Pharm","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"90%"},"publicationCount":515,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"M03BC01","allCodes":["M03BC01","M03BC51","N04AB02"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 May","pmid":"41679394","title":"Neuroprotective potential of orphenadrine in focal cerebral ischemia: A neurobehavioral and mechanistic study.","journal":"Toxicology and applied pharmacology"},{"date":"2025 Dec 1","pmid":"41370840","title":"A Treatment Approach for Severe Pain in Mast Cell Activation Syndrome: A Case Report.","journal":"A&A practice"},{"date":"2025 Sep-Oct","pmid":"41115038","title":"The Physical Compatibility of Orphenadrine Citrate with 0.45% Sodium Chloride, Lactated Ringer's Solution, and Plasma-Lyte A.","journal":"International journal of pharmaceutical compounding"},{"date":"2025 Jul 16","pmid":"40670997","title":"Association of medication adherence and glycemic control with pain severity among patients with diabetes mellitus: a cross-sectional study from Palestine.","journal":"BMC endocrine disorders"},{"date":"2025 May-Jun","pmid":"40582006","title":"Physicochemical and Microbiological Stability of Commonly Prescribed APIs in SyrSpend® SF PH4: A Comprehensive Compatibility Study.","journal":"International journal of pharmaceutical compounding"}],"companionDiagnostics":[],"genericManufacturers":9,"_genericFilersChecked":true,"genericManufacturerList":["Ascot","Hikma","Lupin","Rising","Sagent Pharms","Sandoz","Stevens J","Unichem","Watson Labs"],"status":"approved","companyName":"Pai Holdings Pharm","companyId":"","modality":"Small molecule","firstApprovalDate":"1957","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1957-05-10T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1957-05-10T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1957-05-10T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1957-05-10T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1957-05-10T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1957-05-10T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1988-11-18T00:00:00.000Z","mah":"WATSON LABS","brand_name_local":null,"application_number":"ANDA084779"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1998-05-29T00:00:00.000Z","mah":"GALT PHARMS","brand_name_local":null,"application_number":"ANDA075141"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2003-03-04T00:00:00.000Z","mah":"HIKMA","brand_name_local":null,"application_number":"ANDA040463"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2009-04-27T00:00:00.000Z","mah":"LUPIN","brand_name_local":null,"application_number":"ANDA040284"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2011-08-30T00:00:00.000Z","mah":"SAGENT PHARMS","brand_name_local":null,"application_number":"ANDA090585"},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"Un","currency":"USD","price_amount":"2067.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:41:12.908038+00:00","fieldsConflicting":16,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}